Articles producció científicaMedicina i Cirurgia

Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform

  • Datos identificativos

    Identificador:  imarina:6157903
    Handle: https://hdl.handle.net/20.500.11797/imarina6157903
    Autores:  Garranzo-Asensio, Maria; Guzman-Aranguez, Ana; Povedano, Eloy; Ruiz-Valdepenas Montiel, Victor; Poves, Carmen; Jesus Fernandez-Acenero, Maria; Montero-Calle, Ana; Solis-Fernandez, Guillermo; Fernandez-Diez, Servando; Camps, Jordi; Arenas, Meritxell; Rodriguez-Tomas, Elisabeth; Joven, Jorge; Sanchez-Martinez, Maricruz; Rodriguez, Nuria; Dominguez, Gemma; Yanez-Sedeno, Paloma; Manuel Pingarron, Jose; Campuzano, Susana; Barderas, Rodrigo
    Resumen:
    © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Background and Purpose: The humoral immune response in cancer patients can be used for early detection of the disease. Autoantibodies raised against tumor-associated antigens (TAAs) are promising clinical biomarkers for reliable cancer diagnosis, prognosis, and therapy monitoring. In this study, an electrochemical disposable multiplexed immunosensing platform able to integrate difficult- and easy-to-express colorectal cancer (CRC) TAAs is reported for the sensitive determination of eight CRC-specific autoantibodies. Methods: The electrochemical immunosensing approach involves the use of magnetic microcarriers (MBs) as solid supports modified with covalently immobilized HaloTag fusion proteins for the selective capture of specific autoantibodies. After magnetic capture of the modified MBs onto screen-printed carbon working electrodes, the amperometric responses measured using the hydroquinone (HQ)/H2O2 system were related to the levels of autoantibodies in plasma. Results: The biosensing platform was applied to the analysis of autoantibodies against 8 TAAs described for the first time in this work in plasma samples from healthy asymptomatic individuals (n=3), and patients with high-risk of developing CRC (n=3), and from patients already diagnosed with colorectal (n=3), lung (n=2) or breast (n=2) cancer. The developed bioplatform demonstrated an improved discrimination between CRC patients and controls (asymptomatic healthy individuals and breast and lung cancer patients) compared to an ELISA-like luminescence test. Conclusions: The proposed meth

  • Otros:

    Autor según el artículo: Garranzo-Asensio, Maria; Guzman-Aranguez, Ana; Povedano, Eloy; Ruiz-Valdepenas Montiel, Victor; Poves, Carmen; Jesus Fernandez-Acenero, Maria; Montero-Calle, Ana; Solis-Fernandez, Guillermo; Fernandez-Diez, Servando; Camps, Jordi; Arenas, Meritxell; Rodriguez-Tomas, Elisabeth; Joven, Jorge; Sanchez-Martinez, Maricruz; Rodriguez, Nuria; Dominguez, Gemma; Yanez-Sedeno, Paloma; Manuel Pingarron, Jose; Campuzano, Susana; Barderas, Rodrigo
    Departamento: Medicina i Cirurgia; Ciències Mèdiques Bàsiques
    Autor/es de la URV: Arenas Prat, Meritxell / Joven Maried, Jorge
    Palabras clave: Salsola-kali pollen; Protein; Panel; Liquid biopsy; Identification; Humoral immune-response; Human serum; Halotag fusion proteins; Electrochemical bioplatforms; Early cancer detection; Colorectal cancer; Biosensors; Biosensor; Biomarker determination; Antigens; halotag fusion proteins; electrochemical bioplatforms; early cancer detection; colorectal cancer; biosensor
    Resumen: © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Background and Purpose: The humoral immune response in cancer patients can be used for early detection of the disease. Autoantibodies raised against tumor-associated antigens (TAAs) are promising clinical biomarkers for reliable cancer diagnosis, prognosis, and therapy monitoring. In this study, an electrochemical disposable multiplexed immunosensing platform able to integrate difficult- and easy-to-express colorectal cancer (CRC) TAAs is reported for the sensitive determination of eight CRC-specific autoantibodies. Methods: The electrochemical immunosensing approach involves the use of magnetic microcarriers (MBs) as solid supports modified with covalently immobilized HaloTag fusion proteins for the selective capture of specific autoantibodies. After magnetic capture of the modified MBs onto screen-printed carbon working electrodes, the amperometric responses measured using the hydroquinone (HQ)/H2O2 system were related to the levels of autoantibodies in plasma. Results: The biosensing platform was applied to the analysis of autoantibodies against 8 TAAs described for the first time in this work in plasma samples from healthy asymptomatic individuals (n=3), and patients with high-risk of developing CRC (n=3), and from patients already diagnosed with colorectal (n=3), lung (n=2) or breast (n=2) cancer. The developed bioplatform demonstrated an improved discrimination between CRC patients and controls (asymptomatic healthy individuals and breast and lung cancer patients) compared to an ELISA-like luminescence test. Conclusions: The proposed methodology uses a just-in-time produced protein in a simpler protocol, with low sample volume, and involves cost-effective instrumentation, which could be used in a high-throughput manner for reliable population screening to facilitate the detection of early CRC patients at affordable cost.
    Áreas temáticas: Pharmacology, toxicology and pharmaceutics (miscellaneous); Medicine, research & experimental; Medicine (miscellaneous)
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 18387640
    Direcció de correo del autor: meritxell.arenas@urv.cat; jorge.joven@urv.cat
    Fecha de alta del registro: 2025-03-15
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.thno.org/v10p3022.htm
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Theranostics. 10 (7): 3022-3034
    Referencia de l'ítem segons les normes APA: Garranzo-Asensio, Maria; Guzman-Aranguez, Ana; Povedano, Eloy; Ruiz-Valdepenas Montiel, Victor; Poves, Carmen; Jesus Fernandez-Acenero, Maria; Montero (2020). Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform. Theranostics, 10(7), 3022-3034. DOI: 10.7150/thno.42507
    DOI del artículo: 10.7150/thno.42507
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2020
    Tipo de publicación: Journal Publications

  • Palabras clave:

    Medicine (Miscellaneous),Medicine, Research & Experimental,Pharmacology, Toxicology and Pharmaceutics (Miscellaneous)
    Salsola-kali pollen
    Protein
    Panel
    Liquid biopsy
    Identification
    Humoral immune-response
    Human serum
    Halotag fusion proteins
    Electrochemical bioplatforms
    Early cancer detection
    Colorectal cancer
    Biosensors
    Biosensor
    Biomarker determination
    Antigens
    halotag fusion proteins
    electrochemical bioplatforms
    early cancer detection
    colorectal cancer
    biosensor
    Pharmacology, toxicology and pharmaceutics (miscellaneous)
    Medicine, research & experimental
    Medicine (miscellaneous)

  • Documentos:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar